View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dirk Verbiesen ... (+7)
  • Dirk Verbiesen
  • Marc Hesselink
  • CFA
  • Marc Zwartsenburg
  • CEFA
  • Quirijn Mulder
  • Stijn Demeester

Middle East - Iran turmoil/Impact assessment

In this ING equities impact assessment of the situation in the Middle East report, we focus on a selection of 11 companies which we cover and we expect to be impacted by the current situation in the Middle East following the war in Iran, which started on 28 February and has since spread further into the region. We found that every company in this report faces its own challenges in the short term, while we also discuss the longer-term strategic implications.

 PRESS RELEASE

Participation notifications by The Goldman Sachs Group

Participation notifications by The Goldman Sachs Group Press release                                                                  Regulated information  Brussels, March 18, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), The Goldman Sachs Group, Inc recently sent to Solvay the following transparency notifications. Here is a summary of the notifications:  Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotal March 9, 2026 0.14% 7.08% 7.22%March 10, 20260.25%7.55%7.80% The...

 PRESS RELEASE

Notifications de participation par The Goldman Sachs Group

Notifications de participation par The Goldman Sachs Group Communiqué de presse                                                                 Information réglementée   Bruxelles, le 18 mars 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), The Goldman Sachs Group, Inc a envoyé récemment à Solvay les notifications de transparence suivantes. Voici un résumé des notifications:  Date de dépassement de seuilDroits de voteInstruments financiers équivalentsTotal9 mars 20260,14%7,08%7,22%10 mars 20260,25%7,55%7,80% La der...

 PRESS RELEASE

Participatiemeldingen van The Goldman Sachs Group

Participatiemeldingen van The Goldman Sachs Group Persbericht                                                                 Gereglementeerde informatie  Brussel, 18 maart 2026 - 17u45 CET  In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft The Goldman Sachs Group, Inc onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd. Hier is een samenvatting van de bewegingen:  Datum waarop de drempel werd overschredenStemrechtenAan stemrechten gelijkgestelde financiële instrumentenTotaal9 maart 20260,14%7,08%7,22%10 maart 20260,25%7,55%7,80% De laa...

Heidelberg Materials AG: 1 director

A director at Heidelberg Materials AG bought 159,739 shares at 161.344EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Delphine Brault ... (+2)
  • Delphine Brault
  • Nathan Mietlicki
Delphine Brault ... (+2)
  • Delphine Brault
  • Nathan Mietlicki
 PRESS RELEASE

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designat...

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. The designation is based on data from the LEAP2MONO phase 3 study (clin...

 PRESS RELEASE

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation d...

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026. La Food and Drug Administration (FDA) des États-Unis a accordé la désignation de thérapie innovante au venglustat, un nouvel inhibiteur expérimental de la glucosylcéramide synthase (GCSi) administré par voie orale, pour le traitement des manifestations neurologiques de la maladie de Gaucher de type 3 (MG...

Adecco Group AG: 1 director

A director at Adecco Group AG bought 4,000 shares at 19.300CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

 PRESS RELEASE

Heineken Holding N.V. reports transactions under its current share buy...

Heineken Holding N.V. reports transactions under its current share buyback programme   Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 16 March 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026. From 9 March 2026 up to and including 13 March 2026 a total of 78,015 shares were repurchased on exchange at an average price of € 65.96. Up t...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch